Current Treatment Options for Patients With Multiple Myeloma
In this interview we discuss the standard of care and current treatment options for patients with multiple myeloma.
Hispanics Less Likely to Undergo Transplant for Myeloma
The stem cell transplantation utilization rate in the United States increased from 2008 to 2014, but was lower among Hispanics and non-Hispanic blacks compared with non-Hispanics whites.
Pembrolizumab Combo Active in Relapsed/Refractory Myeloma
Combination treatment with pembrolizumab, pomalidomide, and low-dose dexamethasone resulted in durable responses in patients with relapsed or refractory multiple myeloma.
RVD Plus Transplantation Delayed Progression in Myeloma
Combined treatment with lenalidomide, bortezomib, and dexamethasone plus transplantation significantly delayed progression in patients with multiple myeloma.
Relapsed, Refractory Myeloma Has Indirect Societal Costs
Patients with relapsed or refractory multiple myeloma experienced significant indirect social costs from their disease, in addition to the direct costs.
‘VCD-Lite’ Viable Option for Older, Toxicity-Vulnerable Myeloma Patients
Dose-attenuated bortezomib, cyclophosphamide, and dexamethasone (VCD-lite) is a viable treatment option for vulnerable or frail adults with newly diagnosed multiple myeloma.
Emerging Therapies in Multiple Myeloma
In this interview we discuss the latest therapy developments in the treatment of multiple myeloma.
QOL of Multiple Myeloma Patients Receiving Maintenance Therapy
This interview examines a study that looked at the health-related quality of life of multiple myeloma patients in a real-world setting who underwent maintenance therapy after autologous stem cell transplant.
New Standard of Care in Relapsed, Refractory Myeloma?
In this video, Antonio Palumbo, MD, discusses results of the CASTOR trial, which studied daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
This slide show on multiple myeloma includes images of bone marrow aspirates revealing sheets of tumor cells and organs with amyloid deposits and disease involvement.
By clicking Accept, you agree to become a member of the UBM Medica Community.